GHRP-6

Background/Objective: GHRP-6 is a GH secretagogue hexapeptide with expanding and promising cardioprotective effects. Having determined [dose redacted] as the minimum effective dose for enhancing inotropy based on echocardiographic parameters in healthy rats, we implemented a non-reperfusion myocardial infarct model, with its consequent left ventricle wall thinning and ballooning, via permanent left descending coronary artery ligation. Methods: Rats were assigned to three groups: sham-operated/normal rats, infarcted + saline-treated control rats, and infarcted + GHRP-6-administration rats. Treatments were initiated post-surgery and continued for 7 days. On day 7, the animals were echocardiographically and histologically evaluated. For mitochondrial proteomic analysis, an additional 12 healthy rats were used. Six animals received GHRP-6 or normal saline and were observed for 6 h after the inocul…

open access ↗ · PMID 41901314 · DOI 10.3390/ph19030468

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 41534456 · DOI 10.1016/j.intimp.2026.116204

Renal tubular epithelial cells (TECs), which are highly susceptible to injury during acute kidney injury (AKI), have notable regenerative effects on renal recovery after AKI. AKI-driven metabolic reprogramming of TECs plays a critical role in determining whether kidneys recover functionally or develop fibrosis. Targeting the metabolism of TECs offers valuable insights into AKI treatment. Growth hormone-releasing hormone (GHRH) and its analog GHRH peptide (GHRP) play beneficial roles in the field of regenerative medicine. Here, we designed a self-assembling GHRP-6 peptide hydrogel, and we hypothesized that this hydrogel could reprogram the metabolism of TECs, further enhancing recovery from AKI. Metabolomic sequencing analysis revealed that spermidine, L-glutamine, and acetyl-CoA, which are involved in amino acid and fatty acid metabolism, were highly enriched in a mouse model of AKI trea…

open access ↗ · PMID 41327290 · DOI 10.1186/s12951-025-03888-9

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42461148 · DOI 10.1530/joe-26-0041

The aquaculture industry has experienced considerable growth in recent decades, stimulating research into sustainable and functional feed formulations, mainly related to using high-quality, safe, and environmentally friendly feed ingredients. The employment of immunomodulatory additives is a promising strategy to enhance fish health and performance. In this study, the effects of the ghrelin analog GHRP-6 peptide included in the diet ([dose redacted] of feed) on the endocrine and immune responses of Sparus aurata following Incomplete Freund's adjuvant (IFA) treatment were assessed. After 97 days, fish were intraperitoneally injected with 100 µL of saline solution or IFA/100 g fish and sampled 72 h post-injection. Our results indicated that fish fed GHRP-6 maintained stable plasma levels of lactate, triglycerides, and cortisol after IFA treatment, in contrast to control-fed fish, which showed si…

open access ↗ · PMID 40906090 · DOI 10.3390/biology14080941

BackgroundThe success rate of in vitro maturation (IVM) for human oocytes is clinically significant, prompting a focus on optimizing IVM media culture. While various factors have been incorporated to improve outcomes, the role of Ghrelin hormone, despite its multifunctional nature, remains poorly investigated. This study aimed to determine the most effective concentration of the growth hormone releasing protein-6 (GHRP-6), Ghrelin hormone agonist, in the culture medium.Materials and methodsIn this experimental study, a total of 240 human germinal vesicle (GV) oocytes were collected and cultured in varying concentrations of GHRP-6. Maturation rates were assessed during two days of culture, and compared against a blastocyst media (single-step culture) as control group and another IVM media, human tubal fluid (HTF) 10%, as the sham group. Additionally, the expression levels of two genes ass…

open access ↗ · PMID 41090425 · DOI 10.22074/ijfs.2025.2038272.1745

Ghrelin, the endogenous ligand of the growth hormone secretagogue receptor (GHSR), promotes food intake and other feeding behaviors, and stimulates growth hormone (GH) release from the pituitary. Growth hormone secretagogues (GHS), such as GHRP-6 and MK-0677, are synthetic GHSR ligands that activate orexigenic neuropeptide Y neurons that coexpress agouti-related peptide (AgRP) in the arcuate nucleus of the hypothalamus when administered systemically. Systemic GHRP-6 also stimulates GH release in humans and rats. Thus, GHS and ghrelin have therapeutic relevance in patients who could benefit from its orexigenic and/or GH-releasing effects. This study examined whether intranasal delivery of ghrelin, GHRP-6, or MK-0677 engages the brain ghrelin signaling system. Effective compounds and doses were selected based on increased food intake after intranasal application in mice. Only GHRP-6 (5 mg/…

open access ↗ · PMID 39813130 · DOI 10.1210/endocr/bqae166